IPO Timeline
Broker Results (T-2)
2023-06-27
Some brokers release in afternoon
Grey Market (T-1)
2023-06-28
Afternoon
HKEX Allotment (T-1)
2023-06-28
Evening
Registrar Allotment (T-1)
2023-06-28
Evening
Listing Day (T)
2023-06-29
First day of trading
Company Overview
| Stock Name | 来凯医药－Ｂ |
|---|---|
| Stock Code | 02105 |
| Company Full Name | 来凯医药－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司成立于2016年，是一家以科學為驅動、處于臨床階段的生物醫藥科技公司。 |
| Listing Date | 2023-06-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技園區蔡倫路987號5樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.laekna.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.41 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 86.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 79,088,930 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 6,205 |
| 2 lots | 1,000 | HK$ 12,410 |
| 3 lots | 1,500 | HK$ 18,615 |
| 4 lots | 2,000 | HK$ 24,820 |
| 5 lots | 2,500 | HK$ 31,025 |
| 6 lots | 3,000 | HK$ 37,230 |
| 7 lots | 3,500 | HK$ 43,435 |
| 8 lots | 4,000 | HK$ 49,640 |
| 9 lots | 4,500 | HK$ 55,845 |
| 10 lots | 5,000 | HK$ 62,050 |
| 12 lots | 6,000 | HK$ 74,460 |
| 14 lots | 7,000 | HK$ 86,870 |
| 16 lots | 8,000 | HK$ 99,280 |
| 18 lots | 9,000 | HK$ 111,690 |
| 20 lots | 10,000 | HK$ 124,100 |
| 30 lots | 15,000 | HK$ 186,150 |
| 40 lots | 20,000 | HK$ 248,200 |
| 50 lots | 25,000 | HK$ 310,250 |
| 60 lots | 30,000 | HK$ 372,300 |
| 70 lots | 35,000 | HK$ 434,350 |
| 80 lots | 40,000 | HK$ 496,400 |
| 90 lots | 45,000 | HK$ 558,450 |
| 100 lots | 50,000 | HK$ 620,500 |
| 120 lots | 60,000 | HK$ 744,600 |
| 140 lots | 70,000 | HK$ 868,700 |
| 160 lots | 80,000 | HK$ 992,800 |
| 200 lots | 100,000 | HK$ 1,241,000 |
| 400 lots | 200,000 | HK$ 2,482,000 |
| 600 lots | 300,000 | HK$ 3,723,000 |
| 800 lots | 400,000 | HK$ 4,964,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 500,000 | HK$ 6,205,000 |
| 1,400 lots | 700,000 | HK$ 8,687,000 |
| 1,600 lots | 800,000 | HK$ 9,928,000 |
| 2,000 lots | 1,000,000 | HK$ 12,410,000 |
| 5,000 lots | 2,500,000 | HK$ 31,025,000 |
| 6,373 lots | 3,186,500 | HK$ 39,544,465 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 15.0 |
|---|---|
| First Day Open | HK$ 12.44 |
| First Day Change | 20.87% |
| First Day Volume | 2822000.0 |
| First Day Turnover | 39083600.0 |
Use of Proceeds
| Use of Proceeds | 1、約33.0%或約233.7百萬港元預計將用于迅速推進核心產品之一LAE001的臨床開發及批準； 2、約23.3%或約165.0百萬港元預計將用于推進本公司另一核心產品LAE002的臨床開發及批準； 3、約20.8%或147.4百萬港元預計將用于加快其他現有管線產品的研發，并不斷推進及改進我們的管線產品； 4、約9.9%或70.1百萬港元預計將用于提高產能及發展我們的制造能力； 5、約7.6%或53.8百萬港元預計將用于業務發展活動及增強全球網絡； 6、約5.4%或38.2百萬港元預計將用于營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (1)
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (5)
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
工银国际证券有限公司 CE ARO299
国泰君安证券（香港）有限公司 CE ABY236
农银国际证券有限公司 CE ACX411
Joint Lead Managers (7)
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
工银国际证券有限公司 CE ARO299
国泰君安证券（香港）有限公司 CE ABY236
农银国际证券有限公司 CE ACX411
富途证券国际（香港）有限公司 CE AZT137
华盛资本证券有限公司 CE AUL711
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Asia Partners III, L.P. | 23,510,745 HKD | — | 2.98% | — | 6 months | 2023-12-29 |
| 2 | 宁波姚商燕创宸凯股权投资合伙企业(有限合伙) | 66,840,260 HKD | — | 8.45% | — | 6 months | 2023-12-29 |
| 3 | 先进制造产业投资基金二期(有限合伙) | 117,957,050 HKD | — | 14.91% | — | 6 months | 2023-12-29 |
| 4 | 余姚阳明股权投资基金有限公司 | 471,840,610 HKD | — | 59.66% | — | 6 months | 2023-12-29 |
Directors & Management
| Chairman | 呂向陽 |
|---|---|
| Company Secretary | 柯晨煜 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | OrbiMed Asia Partners III, L.P.(14.84%);呂向陽(12.72%);GP實體(10.49%);ESOP信托(8.75%);北京安龍實體(5.78%) |
|---|
Subscription Tiers
IPO Timeline
